We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+23.08%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$124M
AUM Growth
+$27.8M
(+29%)
Cap. Flow
+$29.5M
Cap. Flow
% of AUM
23.85%
Top 10 Holdings %
Top 10 Hldgs %
54.69%
Holding
32
New
14
Increased
7
Reduced
4
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CMPS
Compass Pathways
CMPS
|
+$7.03M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
+$5.65M |
| 3 |
CytomX Therapeutics
CTMX
|
+$4.57M |
| 4 |
ALMS
Alumis Inc
ALMS
|
+$4.17M |
| 5 |
UroGen Pharma
URGN
|
+$4.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtaiBeckley Inc
ATAI
|
+$7.01M |
| 2 |
IVA
Inventiva
IVA
|
+$4.6M |
| 3 |
ABVX
Abivax
ABVX
|
+$4.29M |
| 4 |
Taysha Gene Therapies
TSHA
|
+$2.51M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$980K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Praxis Precision Medicines
PRAX
$8.77B
| $10.6M | 8.54% |
32,810
+12,928
| +65% | +$4M |
|
2
Minerva Neurosciences
NERV
$199M
| $9.97M | 8.06% |
1,655,500
| – | – |
|
|
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
| $6.7M | 5.41% |
200,000
+31,971
| +19% | +$1.25M |
|
|
SLNO
4
PUT
DELISTED
Soleno Therapeutics
SLNO
| $6.7M | 5.41% |
+200,000
| New | +$7.84M |
|
5
Ovid Therapeutics
OVID
$455M
| $6.26M | 5.05% |
2,818,459
+1,033,459
| +58% | +$1.85M |
|
|
CMPS
6
Compass Pathways
CMPS
$1.67B
| $5.78M | 4.67% |
+1,045,000
| New | +$7.03M |
|
|
7
Tarsus Pharmaceuticals
TARS
$2.61B
| $5.67M | 4.58% |
+80,859
| New | +$5.65M |
|
8
Solid Biosciences
SLDB
$858M
| $5.52M | 4.46% |
766,974
+353,349
| +85% | +$2.27M |
|
9
CALL
Compass Therapeutics
CMPX
$369M
| $5.29M | 4.27% |
+1,000,000
| New | +$5.77M |
|
10
ProMIS Neurosciences
PMN
$136M
| $5.26M | 4.25% |
414,219
+164,880
| +66% | +$2.46M |
|
|
11
Edgewise Therapeutics
EWTX
$4.28B
| $5.07M | 4.1% |
161,000
-34,000
| -17% | -$980K |
|
12
CALL
uniQure
QURE
$2.77B
| $4.91M | 3.96% |
300,000
+100,000
| +50% | +$2.02M |
|
|
EPRX
13
Eupraxia Pharmaceuticals
EPRX
$431M
| $4.78M | 3.86% |
660,375
+262,480
| +66% | +$2.11M |
|
|
14
CytomX Therapeutics
CTMX
$788M
| $4.23M | 3.42% |
+900,000
| New | +$4.57M |
|
|
IVA
15
Inventiva
IVA
$1.09B
| $4.14M | 3.34% |
745,300
-754,700
| -50% | -$4.6M |
|
16
Perspective Therapeutics
CATX
$341M
| $3.86M | 3.12% |
+926,557
| New | +$3.91M |
|
|
ABVX
17
Abivax
ABVX
$11.9B
| $3.75M | 3.03% |
33,712
-36,288
| -52% | -$4.29M |
|
|
ALMS
18
Alumis Inc
ALMS
$3.65B
| $3.68M | 2.97% |
+166,959
| New | +$4.17M |
|
|
19
UroGen Pharma
URGN
$1.96B
| $3.63M | 2.94% |
+202,124
| New | +$4.05M |
|
20
Capricor Therapeutics
CAPR
$1.13B
| $3.46M | 2.8% |
+113,899
| New | +$3.03M |
|
|
MAZE
21
CALL
Maze Therapeutics
MAZE
$1.56B
| $2.98M | 2.41% |
+100,000
| New | +$4.41M |
|
|
WHWK
22
Whitehawk Therapeutics
WHWK
$192M
| $2.82M | 2.28% |
817,939
| – | – |
|
23
Inhibikase Therapeutics
IKT
$331M
| $2.23M | 1.8% |
+1,325,000
| New | +$2.35M |
|
24
CALL
Replimune Group
REPL
$859M
| $1.89M | 1.53% |
246,900
-953,100
| -79% | -$7.29M |
|
25
AN2 Therapeutics
ANTX
$169M
| $1.8M | 1.45% |
+526,315
| New | +$1.09M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q1 2026 Portfolio in Review
As of Q1 2026, Ally Bridge Group held 32 positions worth $124M, up 29% from $96M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Ally Bridge Group deployed $29.5M of net new capital in Q1 2026, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Compass Pathways: 1,045,000 shares worth $5.78M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 66% a quarter earlier.
On the sell side, the largest reduction was Inventiva, an estimated $4.6M trimmed.
- Ally Bridge Group's largest Q1 2026 buy was Compass Pathways: 1,045,000 shares worth $5.78M.
- Ally Bridge Group added most to Praxis Precision Medicines in Q1 2026, an estimated $4M increase.
- Ally Bridge Group's biggest Q1 2026 reduction was Inventiva, cutting an estimated $4.6M.
- Ally Bridge Group fully exited AtaiBeckley Inc in Q1 2026, selling an estimated $7.01M.
- Ally Bridge Group's ten largest holdings make up 55% of its $124M portfolio in Q1 2026.
- Ally Bridge Group opened 14 new positions and closed 5 in Q1 2026.
- Ally Bridge Group's portfolio value rose 29% quarter-over-quarter to $124M.
Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.